Activation of platelets by eosinophil granule proteins by unknown
A
n association between activated eosinophils and platelets
has been described in the pathology of several diseases,
most notably asthma (1-3) and hypereosinophilic syndrome
(4, 5) . Upon activation, the eosinophil releases four main
granule proteins ; major basic protein (MBP), eosinophil-
derived neurotoxin (EDN), eosinophil cationic protein (ECP),
and eosinophil peroxidase (EPO), into the extracellular fluid
(6-8), where they are able to exert a variety of biological ac-
tions (9, 10) . For example, both MBP and ECP are potent
helminthotoxins, whileEDN is a weaker helminthotoxin (11) .
MBP is also cytotoxic for mammalian cells and likely acts
as a mediator of tissue damage in bronchial asthma (12, 13) .
EDN and ECP produce the Gordon phenomenon, a neuro-
logic syndrome characterized by stiffness, muscle weakness,
and wasting and ataxia, when injected into rabbits or guinea
pigs (14, 15) . EPO exhibits pronounced cytotoxic activity
when combined with hydrogen peroxide and a halide, and
has been shown to be an agonist for mast cell degranulation
(16, 17) . Given the wide range ofbiological activities of the
eosinophil granule proteins, we hypothesized that one or more
of these proteins may be a platelet agonist . The results of
studies that support this hypothesis are described here.
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Summary
Two of the four principal cationic proteins of the eosinophil granule, major basic protein (MBP)
and eosinophil peroxidase (EPO), wereshown to be platelet agonists. Both MBP andEPO evoked
a dose-dependent nonlytic secretion ofplatelet 5-hydroxytryptamine in unstirred platelet suspensions
even in the presence of 10 /,M indomethacin . MBP also evoked secretion of platelet a granule
and lysosome components. Secretion by MBP and EPO was inhibited by 1 14M PGE,, but the
nature of the inhibition differed from that observed with thrombin . Thus, MBP and EPO can
be classified as strong platelet agonists with a distinct mechanism of activation .
Purification ofEosinophil Granule Basic Proteins.
￿
The four pro-
teins, MBP, EPO, ECP, and EDN, that constitute the main basic
eosinophil granule basic proteins were purified to physical homo-
geneity from the eosinophils ofpatients with hypereosinophilic syn-
drome as previously described (18-20) .
Preparation and f4CJ5-Hydroxytryptamine Loading of Washed
Human Platelets. Freshly drawn platelet-rich plasma from healthy
normal adult blood donors was obtained from the Mayo Blood Bank.
Platelets were isolated from this platelet-rich plasma as previously
described (21) . The washed platelets were resuspended in Tyrode's
buffer at a concentration of 2 x 10 8 cells/ml for all studies except
those used in the measurement of the secretion of a-N-acetyl-
glucosaminidase (/3-NAGase), where the platelet concentration was
5 x 108 cells/ml . Platelets to be used to assay 5-hydroxytrypt-
amine secretion were loaded with ['°C]5-hydroxytryptamine be-
fore resuspension in Tyrode's buffer (21) .
Assay of 5-Hydroxytryptamine, ,B-Thromboglobulin, and ,B-NAce-
tylglucosaminidase Secretion . For all studies involving measurement
of5-HT secretion, unstirred reaction mixtures containing 100 pl
of [14C15-HT loaded, washed platelets and 15 P.1 of the various eo-
sinophil granule proteins were incubated for 15 min at room tem-
perature. Secretion was terminated by the addition of 15 Ecl of8%
paraformaldehyde, and the reaction was centrifuged to pellet the
platelets. Aliquots ofthe supernatant were counted to quantify5-HT
release . Release is reported as a percentage of the total platelet
1"C15-HT, as determined by treatment of the loaded platelets with
2% Triton X-100 . All reactions were performed in duplicate . For
studies in which the effect of indomethacin or PGE, on 5-HT
secretion was examined, the washed, loaded platelets were treated
with freshly prepared 10 p.M indomethacin or 1 uM PGE, for 15
min before stimulation with the eosinophil granule proteins .
For studies measuring the secretion off3-thromboglobulin (0-TG)
and /3-NAGase, the reaction mixtures contained 500 P.l of washed,
unloaded platelets and 50 P.1 ofeosinophil proteins . The reactions
were terminated after 15 min at room temperature by centrifuga-
tion through a 1:1 mixture ofApezion A oil (Biddle Instruments,
Blue Bell, PA) and butyl phthalate, since paraformaldehyde is known
to interfere with the assay of these components. Aliquots of the
resulting aqueous upper layer were then assayed as previously de-
scribed (22) for 0-TG and ,Q-NAGase using a RIA and a spec-
trophotometric assay, respectively.
Results and Discussion
When unstirred suspensions of ( 14C]5-HT loaded, washed
human platelets were exposed to purified preparations ofthe
four eosinophil granule proteins, only MBP andEPO evoked
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Figure 1 .
￿
Dose-response curves for the secretion of platelet 5-HT by
eosinophil granule proteins. Shown are the dose-dependencies for secre-
tion of [ 14C]5-HT from washed human platelets mediated by MBP (" ),
EPO (O), ECP (/), and EDN (EI) . The secretion is expressed as a per-
centage of the total platelet [ 14C]5-HT. The values shown represent the
mean ± SEM 5-HT secretion determined from seven independent platelet
preparations for MBP and EPO, and two independent platelet prepara-
tions for ECP and EDN .
the dose-dependent release of 5-HT (Fig . 1) . Both proteins
released -60-70% of the total 5-HT with EC50s of 28 and
20 Ag/ml for MBP and EPO, respectively. This release was
due to secretion rather than to toxic damage (12, 16, 23) to
the platelets because MBP and EPO released only 1% and
4% of the total platelet lactate dehydrogenase under condi-
tions where maximal 5-HT release occurred . In contr4st to
the 5-HT secretion evoked by MBP and EPO, neither ECP
norEDN stimulated appreciable secretion of5-HT This ob-
servation suggests that the secretion by MBP or EPO is not
simply due to the highly cationic nature of the proteins be-
cause ECP and MBP have essentially identical pIs (24) . Fur-
thermore, several pieces of evidence suggest that the secre-
tion mediated byEPO was not due to its enzymatic activity.
First, EPO promoted secretion in the absence of exogenously
added substrates, hydrogen peroxide, and bromide or iodide.
Second, EPO induced the same amount of 5-HT secretion
in the presence of 1,100 U/ml of catalase, a concentration
of catalase sufficient to degrade any endogenously produced
hydrogen peroxide. Finally, heparin, which had no effect on
the catalytic activity ofEPO, inhibited EPO-dependent secre-
tion, presumably by binding to the EPO. In this regard, the
activation of platelets by EPO differs from the EPO mecha-
nism of mast cell activation . Mast cell secretion by EPO has
been shown to be absolutely dependent on the enzymatic
activity ofEPO and required exogenously added hydrogen
peroxide and halide (17) .
The secretion of 5-HT induced by MBP orEPO was not
dependent upon the production of cyclo-oxygenase metabo-
lites of arachidonic acid . As shown in Fig. 2, the presence
of 10 aM freshly prepared indomethacin, a concentration
sufficient to inhibit completely platelet thromboxane A2 for-
mation (25), had no effect on the dose-response curves for
5-HT release mediated by MBP or EPO. Also shown as a
control in Fig. 2 is the inefficacy ofindomethacin on thrombin-
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Figure 2 .
￿
Effect of indomethacin on the MBP and EPO dose-response
curves for platelet 5-HT secretion . Shown are the dose dependencies for
the secretion of [ 14C]5-HT from washed human platelets mediated by
MBP (A), EPO (B), and human thrombin (C) . In each panel, the dose-
response curves for [14C]5-HT secretion from untreated, control platelets
(O) and platelets preincubated for 15 min with 10 p,M indomethacin (" )
are depicted. The secretion is expressed as a percentage ofthe total platelet
( 14C]5-HT . The values shown are the mean ± SEM secretion from the
platelets of four independent donors for MBP and EPO and three inde-
pendent donors for thrombin .
mediated 5-HT secretion . Detwiler and colleagues (26, 27)
have proposed that platelet agonists can be divided into weak
and strong categories . Strong agonists are capable ofpromoting
secretion from unstirred platelet suspensions, and the secre-
tion is independent of thromboxane A2 formation . Based on
our observations, both MBP and EPO can be classified as
strong platelet agonists.
Although not originally proposed by Detwiler and col-
leagues as a criterion for strong agonists, several investigators
have shown that secretion of lysosomal enzymes is a prop-
erty restricted to strong agonists (28) . As depicted in Fig.
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Figure 3 .
￿
Dose-response curves for the MBP-dependent secretion of
platelet 5-HT, (3-thromboglobulin, and (3-N-acetylglucosaminidase . Shown
are the dose-response curves for the secretion of [ 14C]5-HT (O) from the
platelet dense granules, 0-thromboglobulin (") from the a granules, and
/3-N-acetylglucosaminidase (0) from the lysosomes of washed, human
platelets. The secretion is reported as a percentage ofthe total plateletcon-
tent of 5-HT, 0-TG, or l3-NAGase. The values shown are the mean secre-
tion from the platelets from three independent donors .a
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￿
Effect of PGE1 on the MBP and EPO dose-response curves
for platelet 5-HT secretion . Shown are the dose dependencies for the secre-
tion of [ 14C]5-HT from washed human platelets mediated by MBP (A),
EPO (B), and human thrombin (C) . In each panel, the dose-response curves
for 114C]5-HT secretion from untreated, control platelets (O) and platelets
preincubated for 15 min with 1 AM PGE1 (" ) are depicted . The secre-
tion is expressed as a percentage of the total platelet 1 14C]5-HT The values
shown are the mean ± SEM secretion from the platelets of three indepen-
dent donors forMBP and thrombin and the mean ± range secretion from
the platelets of two independent donors for EPO .
3, MBP promotes the secretion of components of the dense
granules, a granules, and lysosomes in a dose-dependent
manner. The similarity in extent of secretion and MBP dose
requirements for secretion from the dense and a granules,
along with the lesser release from lysosomes at higher MBP
concentrations, is consistent with the effects reported for other
strong platelet agonists (28) . As expected from their failure
to induce 5-HT secretion, both EDN and ECP also failed
to induce secretion of 0-TG from the a granules (data not
shown) .
Although both MBP and EPO can be classified as strong
platelet agonists, their mechanism of platelet activation ap-
pears to differ from that of other strong platelet agonists based
on the effect of PGEI on platelet activation . PGEI is an in-
hibitor of platelet activation by all known platelet agonists.
It is believed to act by increasing the cellular level ofc-AMP,
which, in turn, activates ac-AMP protein kinase. Activation
ofthis protein kinase results in the phosphorylation of a platelet
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protein thought to regulate cytosolic calcium concentrations
with the resulting inhibition ofplatelet granule secretion (29) .
As illustrated in Fig . 4, the strong platelet agonist thrombin
can overcome this inhibition at sufficiently high agonist levels.
The rightward shift in the secretion dose-response curve in
the presence ofPGE1 is typical of the effect of PGEI on pre-
viously described strong platelet agonists (30, 31) . The effect
of 1 p.M PGEI on MBP- and EPO-mediated secretion is,
however, quite different . PGE I had relatively little effect on
5-HT secretion at low levels of these agonists but reduced
the maximal secretion by 30-50% without shifting the dose
curves. Additional studies indicated that high doses ofPGE I
had no additional effect on secretion (data not shown) . These
results suggest that the mechanism of platelet activation by
MBP andEPO is distinctly different from that ofother strong
platelet agonists.
Activation of platelets by eosinophil granule proteins may
play a role in the pathogenesis of several diseases. The de-
granulation of eosinophils and subsequent release of granule
proteins in the airways may provide a mechanism for the local-
ized activation of extravascular platelets in asthma . Abnor-
malities ofplatelet function have been shown in patients with
asthma . Also, platelets recovered from the bronchoalveolar
lavage fluid from asthmatic patients are often associated with
eosinophils and show evidence ofdegranulation (1, 2) . In these
patients, MBP has been found deposited on the damaged re-
spiratory epithelium (1, 12, 13) and also recovered in bron-
choalveolar lavage fluid (32) and sputum (13) at concentra-
tions consistent with those required for platelet activation
found in this study. Platelet activation by MBP andEPOmay
also be important in other diseases characterized by high levels
of eosinophils, such as hypereosinophilia syndrome. This dis-
ease is characterized by high levels of blood eosinophils and
cardiac involvement associated with the formation of mural
thrombi and emboli (4, 5) . MBP is deposited on the en-
docardium and intima of blood vessels at the sites where
thrombus formation almost uniformly occurs (33) . Platelet
activation by the depositedMBPmay provide an explanation
for the close association between eosinophil degranulation
and thrombus formation in this disease .
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